

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

_			www.uspio.gov	
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/848,107	05/03/2001	Egon Persson	6176.200-US	7628
	7590 05/05/2004	EXAMINER		
NOVO NORDISK PHARMACEUTICALS, INC 100 COLLEGE ROAD WEST			SNEDDEN, SHERIDAN	
PRINCETON,	NY 08540		ART UNIT	PAPER NUMBER
			1653	
			DATE MAILED: 05/05/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	•		Application No.	Applicant(s)
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE of THIS COMMUNICATION. A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. THE MAILING DATE OF THIS COMMUNICATION. A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE XINGUITING be assigned and the property of the production of the production of 7 CFR 1.136(s). In no event, however, may a reply be limely filled and the XINGUITING be assigned because the production of the XINGUITING because the production of the XINGUITING because the separation of the XINGUITING because the production to become ARAMONED GS U.S.C. § 133. Cannot place the mailing date of the communication. A production of the XINGUITING because the mailing date of the communication, even if thenly filled, may reduce any reduce any reply received by the set of extended period for reply will, by statute, cause the application to become ARAMONED GS U.S.C. § 134. Cannot any reply received by the set of extended period for reply will, by statute, cause the application to become ARAMONED GS U.S.C. § 134. Cannot any reduce a	Office Action Summer		09/848,107	PERSSON ET AL.
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MULLING DATE OF THIS COMMUNICATION. Extension of the property of the month of the procession of 3 CPR 1-15(a). In no event, however, may a reply be limely filed after \$1.6 (a) MONTHS from the month of the procession of 3 CPR 1-15(a). In no event, however, may a reply be limely filed after \$1.6 (a) MONTHS from the month of the procession of 3 CPR 1-15(a). In no event, however, may a reply be limely filed after \$1.6 (a) MONTHS from the month of the procession of the proces	Onice Acadii Sun	Titiary	Examiner	Art Unit
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions or bein may be valuable under the provisions of 3 C/R1 1.13(a). In no event, however, may a reply be timely filed after 6 SIX (6) MCNTHS from the mailing date of this communication. **SHORT OF THE COMMUNICATION OF THE CO	The Beauty of		Sheridan K Snedden	1653
Extensions of time may be available under the information of the common author. Extensions of time may be available under the information of the common author. If the period for reply specified above it is essentially the common author. If the period for reply specified above it is essentially the common author. If the period for reply specified above, the maximum statutory period will apply and will experible SIX (e) MORTHS from the mailing date of the communication. Any reply received by the Office settlened period for reply with the asplication to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office settlened period for reply with. By a statute, cause the application to become ABANDONED (35 U.S.C. § 133). Status 1) A Responsive to communication(s) filed on 12/19/2004. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-13 and 24-28 is/are pending in the application. 4a) Of the above claim(s) none is/are vithdrawn from consideration. 5) Claim(s) 1-13 and 24-28 is/are objected to. 3) Claim(s) 1,2,7,8,1-11,32,4,25,27 and 28 is/are rejected. 7) Claim(s) 1,2,7,8,1-11,32,4,25,27 and 28 is/are rejected. 7) Claim(s) 3-6.9 and 26 is/are objected to. 3) Claim(s) 1,2,8,1-11,32,4,25,27 and 28 is/are rejected. 7) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). The cath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. **Torrity under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or	Period for Reply	is communication	appears on the cover sheet wi	ith the correspondence address
Status 1) Responsive to communication(s) filed on 12/19/2004. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-13 and 24-28 is/are pending in the application. 4a) Of the above claim(s) none is/are withdrawn from consideration. 5) Claim(s)	- Extensions of time may be available under after SIX (6) MONTHS from the mailing dat - If the period for reply specified above is les - If NO period for reply is specified above, the Failure to reply within the set or extended p Any reply received by the Office later than the set of the set of the set or extended p and the set or extended possible set or extende	the provisions of 37 CF te of this communication is than thirty (30) days, are maximum statutory period for reply will, by status and three months after the maximum status and three months after the maximum status.	JN. R 1.136(a). In no event, however, may a note in the statutory minimum of thirts are ply within the statutory minimum of thirts and will apply and will expire SIX (6) MON	reply be timely filed by (30) days will be considered timely. ITHS from the mailing date of this communication
2a) ☐ This action is FINAL. 2b) ☐ This action is non-final. 3 ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4 ☐ Claim(s) 1-13 and 24-28 is/are pending in the application. 4a) Of the above claim(s) none is/are withdrawn from consideration. 5 ☐ Claim(s)	• • • • • • • • • • • • • • • • • • • •	Κ 1.70 4 (0).		
2a) ☐ This action is FINAL. 2b) ☐ This action is non-final. 3 ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4 ☐ Claim(s) 1-13 and 24-28 is/are pending in the application. 4a) Of the above claim(s) none is/are withdrawn from consideration. 5 ☐ Claim(s)	1) Responsive to communica	otion(e) filed on 1	0/40/0004	
Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims	2a)☐ This action is FINAL .			
Disposition of Claims 4)		. حارت. condition for allo	His action is non-illiar.	
A) Claim(s) 1-13 and 24-28 is/are pending in the application. 4a) Of the above claim(s) none is/are withdrawn from consideration. 5] Claim(s)	closed in accordance with	the practice und	er Ev parte Ouavie, 1035 C.D.	ers, prosecution as to the merits is
4) Claim(s) 1-13 and 24-28 is/are pending in the application. 4a) Of the above claim(s) none is/are withdrawn from consideration. 5) □ Claim(s) is/are allowed. 6) □ Claim(s) 1.2.7.8.10-13.24.25.27 and 28 is/are rejected. 7) □ Claim(s) 3-6.9 and 26 is/are objected to. 8) □ Claim(s) are subject to restriction and/or election requirement. Application Papers 9) □ The specification is objected to by the Examiner. 10) □ The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) □ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. riority under 35 U.S.C. § 119 12) □ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) □ All b) □ Some * c) □ None of: 1. □ Certified copies of the priority documents have been received. 2. □ Certified copies of the priority documents have been received in Application No 3. □ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.		tito praedec a	איס פרא parte wuayie, וייס סיים.	. 11, 453 O.G. 213.
4a) Of the above claim(s) none is/are withdrawn from consideration. 5				
5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are allowed. 7) ☐ Claim(s) 26.9 and 26 is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or election requirement. Application Papers 9) ☐ The specification is objected to by the Examiner. 10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. riority under 35 U.S.C. § 119 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some * c) ☐ None of: 1. ☐ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Acknowledgment is made of a claim for foreign priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Acknowledgment is made of a claim for foreign priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Acknowledgment is made of a claim for foreign priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of th	4)⊠ Claim(s) <u>1-13 and 24-28</u> is	/are pending in th	he application.	
6) ☐ Claim(s) 1,2,7,8,10-13,24,25,27 and 28 is/are rejected. 7) ☐ Claim(s) 3-6,9 and 26 is/are objected to. 8) ☐ Claim(s) 3-6,9 and 26 is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or election requirement. Application Papers 9) ☐ The specification is objected to by the Examiner. 10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. riority under 35 U.S.C. § 119 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some * c) ☐ None of: 1. ☐ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Acknowledgment is made of a claim for foreign priority documents have been received in Application No 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).	4a) Of the above claim(s) <u>n</u>	one is/are withdr	awn from consideration.	
Total Claim(s) 3-6,9 and 26 is/are objected to. Claim(s) are subject to restriction and/or election requirement.				
Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. riority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.	6) Claim(s) <u>1,2,7,8,10-13,24,2</u>	<u>25,27 and 28</u> is/a	re rejected.	
application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. riority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Application Disclosure Statement(s) (PTO-1449 or PTO/58/08)	7) Claim(s) <u>3-6,9 and 26</u> is/are	e objected to.		
9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. riority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.	8) Claim(s) are subject	to restriction and	d/or election requirement.	
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. riority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.	Application Papers			
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. riority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.	9) The specification is objected	I to by the Exami	inar	
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. riority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. All Interview Summary (PTO-413) Paper No(s)/Mail Date. Notice of Informal Patent Application (PTO-152)	10)☐ The drawing(s) filed on	is/are: a)∏ a	accepted or hIP objected to be	·· <u> </u>
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. riority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some colonic None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. All b Interview Summary (PTO-413) Paper No(s)/Mail Date. Paper No(s)/Mail Date. Discosure Statement(s) (PTO-1449 or PTO/SB/08) Notice of Informal Patent Application (PTO-152)	Applicant may not request that	any objection to the	ccepted of D)_1 objected to by	y the Examiner.
riority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Interview Summary (PTO-413) Paper No(s)/Mail Date. Interview Summary (PTO-413) Paper No(s)/Mail Date. Notice of Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)	Replacement drawing sheet(s)	including the corre	ne drawing(s) be neid in abeyance	e. See 37 CFR 1.85(a).
riority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). All b) Some * c) None of the priority documents have been received. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). All b) Some * c) None of the priority documents have been received in this National Stage application for a list of the certified copies not received. All b) Some * c) Notice of priority documents have been received. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).	11) The oath or declaration is ob	piected to by the	ection is required it the drawing(s) Examiner: Note the attached () is objected to. See 37 CFR 1.121(d).
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). All b) Some * c) Notice of the priority documents have been received. Application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Application from the International Bureau (PTO-413) Paper No(s)/Mail Date Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Notice of Informal Patent Application (PTO-152)		,	manner role are enderion a	Jinice Action or form PTO-102.
a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Notice of References Cited (PTO-892)	<u> </u>			
1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. **Acchment(s) Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Discoure Statement(s) (PTO-1449 or PTO/SB/08) **Description of the priority documents have been received in Application No 1. Interview Summary (PTO-413) Paper No(s)/Mail Date 5) Notice of Informal Patent Application (PTO-152)	12) Acknowledgment is made of	a claim for foreig	n priority under 35 U.S.C. § 1	19(a)-(d) or (f).
2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. **Cachment(s)* Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) **Described (PTO-152) **Authorized to Provide the Provided Head of the priority documents have been received in this National Stage application No **Interview Summary (PTO-413) Paper No(s)/Mail Date **Described (PTO-152)				
See the attached detailed Office action for a list of the certified copies not received. **See the attached detailed Office action for a list of the certified copies not received. **See the attached detailed Office action for a list of the certified copies not received. **See the attached detailed Office action for a list of the certified copies not received. **See the attached detailed Office action for a list of the certified copies not received. **Achment(s)** Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) **Description** Notice of Informal Patent Application (PTO-152)	Continued Copies of the	priority documer	nts have been received.	
See the attached detailed Office action for a list of the certified copies not received. **See the attached detailed Office action for a list of the certified copies not received. **See the attached detailed Office action for a list of the certified copies not received. **See the attached detailed Office action for a list of the certified copies not received. **See the attached detailed Office action for a list of the certified copies not received. **Achment(s)** Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) **Description** Notice of Informal Patent Application (PTO-152)	Z. Certified copies of the	priority documer	nts have been received in App	lication No
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. **Cachment(s) Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) **June 17.2(a)) Interview Summary (PTO-413) Paper No(s)/Mail Date Notice of Informal Patent Application (PTO-152)	5. Copies of the Certified	copies of the pri	ority documents have been re	ceived in this National Stage
Achment(s) Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Page No.(3)/Mail Date Notice of Informal Patent Application (PTO-152)	application from the in	nternational Burea	au (PCT Rule 17,2(a)).	
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Page No.(3)/Mail Date Notice of Informal Patent Application (PTO-152)	See the attached detailed Onli	ce action for a lis	it of the certified copies not red	ceived.
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Page No.(3)/Mail Date Notice of Informal Patent Application (PTO-152)				
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Pager No(s)/Mail Date. Notice of Informal Patent Application (PTO-152)	achment(s)			
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Pager No(s)/Mail Date. Notice of Informal Patent Application (PTO-152)	Notice of References Cited (PTO-892)		4) T Interview Sum	······································
☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) 5) ☐ Notice of Informal Patent Application (PTO-152)	Notice of Draftsperson's Patent Drawing F	Review (PTO-948)	Paper No(s)/M	lail Date
Fabel Norsymall 1976	Information Disclosure Statement(s) (PTO Paper No(s)/Mail Date	1-1449 or PTO/SB/08	5) Notice of Inform 6) Other:	mal Patent Application (PTO-152)

Art Unit: 1653

DETAILED ACTION

Response to Amendment

1. This Office Action is in response to Paper filed 19 December 2003. Claims 14-23 and 29 have been canceled. Claims 1-13 and 24-28 are under examination.

Withdrawal of Objections and Rejections

2. The objections and/or rejections not explicitly restated or stated below are withdrawn.

Maintained Objections and Rejections

Double Patenting

3. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Art Unit: 1653

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

4. Claims 1-2, 7, 8, 10-13, 24-25, 27-28 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1, 4, 6 and 7 of copending Application No. 10/109,498. Although the conflicting claims are not identical, they are not patentably distinct from each other because scope of the claims are directed to identical subject matter. For instance, claims 1 and 7 of Application No. 10/109,498 recites a variant Factor VII peptide with at least one amino acid substitution. Claim 5 and 6 teach the substitution of Leu 305 with a Valine residue. Claims 1, 5, and 6 specifies the substitution of Leu 305 with either Val, Ile, or Tyr, where the variant exhibits increased bioactivity.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. Applicant may overcome this rejection by amending or canceling the conflicting claims in the current application or copending Application No. 10/109,498.

Applicant argues that a terminal disclaimer was filed with the response. However, the terminal disclaimer for 10/109,498 was not found in the file. Only, the terminal disclaimer regarding application 10/255,032 was present.

Art Unit: 1653

Maintained Objections and Rejections

Double Patenting

5. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

6. Claims 1-2, 7, 8, 24-25, 27-28 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1, 4, 6 and 7 of copending Application No. 10/281,727. Although the conflicting claims are not identical, they are not patentably distinct from each other because scope of the claims are directed to identical

Art Unit: 1653

subject matter. For instance, claims 1, 5 and 8 of Application No. 10/281,727 recites a variant Factor VII peptide with the substitution of Leu 305 with any amino acid residue.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. Applicant may overcome this rejection by amending or canceling the conflicting claims in the current application or copending Application No. 10/281,727.

Claim Rejections - 35 USC § 102

7. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- 8. Claims 1, 7, 24, and 27 are rejected under 35 U.S.C. 102(e) as being anticipated by Pedersen *et al.* (US 2003/0096338 A1). Pedersen *et al.* teach the a Factor VII polypeptide where L305 is substituted with Asn (see section [0126] and claim 44). These compounds would inherently possess the increased activity. The compounds are used in the treatment of bleeding episodes that would enhance homeostasis (see section [0011]). Thus, the reference anticipates the claimed invention.

Art Unit: 1653

Claim Rejections - 35 USC § 103

- 9. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-2, 7, 8, 24-25, 27-28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Dickinson et al. (Proc. Natl. Acad. Sci. USA 93, 14379-14384, 1996), and further in view of the Pedersen *et al.* (US 2003/0096338 A1), the Dictionary of Biochemistry and Molecular Biology (John Wiley & Sons, 2d ed. 1989), and Berkner *et al.* (US 5288629 A).

Dickinson et al. relates to Factor VII polypeptides wherein L305 has been replaced by Ala. Dickinson et al. teach that the substitution in the loss of proteolytic function. Dickinson et al. does not teach the above substitutions with any other amino acid other than Alanine. Dickinson et al. does not teach use of the peptides for the treatment of bleeding episodes.

Pedersen *et al.* teach the a Factor VII polypeptide where L305 is substituted with Asn (see section [0126] and claim 44). The compounds are used in the treatment of bleeding episodes that would enhance homeostasis (see section [0011]).

In the area of biotechnology, peptide may differ by a conservative substitutions defined as "the replacement in a protein of one amino acid by another, chemically similar, amino acid... [which] is generally expected to lead to either no change or only a small change in the properties of the protein." Dictionary of Biochemistry and Molecular Biology 97 (John Wiley & Sons, 2d ed. 1989).

Art Unit: 1653

Berkner *et al.* teach the use of a modified Factor VII molecule with reduces proteolytic function in a method treating bleeding episodes and or to enhance homeostasis. Berkner *et al.* teach that the reduced proteolytic function may be accompanied by fewer undesirable side effects than experienced with current therapies, as it would not lead to the degradation of other clotting factors.

Thus, it would have been it would have been obvious to the person of ordinary skill in the art at the time the invention was make conservative substitutions at L305 of Factor VII with amino acids conservative to Asn and Ala. Dickinson *et al.* teach that the substitutions at L305 result in the loss of proteolytic function, which as suggested by Berkner *et al.* is the desired activity required for treating bleeding episodes. Thus, it can at least be expected that similar substitution at the given positions would result in like activity. A person of ordinary skill in the art would have been motivated to make the above substitutions in order to create a variant with reduced proteolytic function that would act to interrupt the clotting cascade. Thus, the claimed invention was within the ordinary skill in the art to make and use at the time it was made and was as a whole, *prima facie* obvious.

Claim Objections

10. Claims 3-6, 9, 26 are objected to because of the following informalities: the claims are dependent are rejected claims. Appropriate correction is required.

Art Unit: 1653

Conclusion

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sheridan K Snedden whose telephone number is (571) 272-0959. The examiner can normally be reached on Monday - Friday, 8:30 AM to 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on (571) 272-0951. The fax phone number for regular communications to the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

SKS April 30, 2004

SKS

CHRISTOPHER S. F. LOW SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600

Page 8